Company intelligence / Profile preview

Pluri Consultants

Haifa, Haifa, Israelpluri.ro ↗

Ownership: Private
Employees: ~112
Development stage: Other

Overview

Pluri has advanced its lead product candidate Emiplacel to Phase 3 for muscle injury indications. Avoplacel is in Phase 2 for acute radiation syndrome. The company also has an early-stage MAIT cell immunotherapy platform targeting solid tumors. Clinical results have shown promise in regenerative medicine applications.

Therapeutic areas: OtherOncologyHematology
Modalities: Mesenchymal stem cell therapyCell therapyStem cell therapy
Industry: Biotech

Partnerships

Bar-Ilan University collaboration on cancer immunotherapyTnuva Food Industries partnership via Ever After Foods

Beyond the preview

Go deeper on Pluri Consultants.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Pluri Consultants.

Explore the full profile